Welcome to our June research update! Getting involved with research is an important way to impact food allergy treatments, education, and awareness.
This month, we are highlighting research opportunities and news on:
- Early introduction of peanut prevents peanut allergy in older children
- Clinical trial for children with peanut allergy
- Clinical trial for teens and adults with eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD)
Note: The links below will take you to external websites.
Clinical Trials
Now Enrolling: The VITESSE Phase 3 Study for Peanut Allergy
The VITESSE phase 3 clinical research study is looking for children 4 to 7 years of age who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet. Study doctors are testing an investigational drug patch (also called study drug patch) to learn how well it works and how safe it is in children with peanut allergy.
- What should I know about the VITESSE study?
- To be eligible for this study, participants must be*:
- 4 to 7 years of age
- Diagnosed with peanut allergy
- Currently following a strict peanut-free diet
*Other inclusion/exclusion criteria will apply.
- This study will consist of at least 12 study visits and 5 phone calls over a period of approximately 58 weeks (about 1 year)
- Participants will be randomly assigned (by chance) to receive the study drug patch or placebo patch (looks like the study drug but contains no active drug). Participants will have about a 67% (2 in 3) chance of receiving the study drug patch and about a 33% (1 in 3) chance of receiving the placebo patch
- The health and safety of participants will be monitored throughout the study
- Participant data and information will be kept confidential according to applicable laws for clinical research studies
- Study participants will receive all study-related procedures and the study drug patch or placebo patch at no cost
To learn more about the VITESSE phase 3 study and eligibility criteria, please visit VitesseAllergyStudy.com or ClinicalTrials.gov (identifier: NCT05741476).
Study sponsored by DBV Technologies
Is Eosinophilic Gastritis with or without Eosinophilic Duodenitis Affecting Your Daily Life?
You may be eligible for the Engage clinical study, which aims to investigate a study drug for EoG with or without EoD.
You may be eligible if you:
- Are âĨ 12 years old
- Have been diagnosed with EoG by endoscopic biopsy
- Have had at least 2 EoG episodes every week in the 8 weeks prior to joining the study (stomach pain, stomach cramping, nausea, bloating, early satiety, loss of appetite, vomiting, diarrhea)
There are other requirements to participate. To learn more about Engage, and whether it may be right for you, please visit the study website.
Protocol Number: R668-EGE-2213
ÂĐ Regeneron Pharmaceuticals, Inc. All rights reserved.
Friends in the NY Metropolitan Area: Does Your Mouth Itch or Tingle When You Eat Raw Fruit or Vegetables? Do You Have Oral Allergy Syndrome (OAS)?
Do you have these symptoms? Would you like to contribute to important new clinical research? You may be qualified to participate in a new research initiative with an investigational medicine.
Eligible participants may receive compensation for time and travel.
Sponsored by Aquestive
Latest Food Allergy News
Introducing Peanut to Infants Helps Prevent Peanut Allergy in Later Childhood
Peanuts are one of the most common food allergies in children. It was discovered years ago that waiting to introduce peanut to babies leads to more peanut allergy. This study set out to determine if introducing peanut early would continue to protect against allergy in later childhood.
This study was called LEAP-Trio study, supported by the National Institute of Allergy and Infectious Diseases (NIAID). The study was built on earlier research from the Learning Early About Peanut Allergy (LEAP) clinical trial, and the later LEAP-On study.
In the LEAP study, half of the children ate peanuts regularly from infancy to age 5, while the other half avoided them. At age 5, the peanut-eating group had an 81% lower risk of peanut allergies. In the LEAP-On study, a continuation of the LEAP study, children were asked to avoid peanuts from ages 5 to 6. The results showed the children who ate peanuts during the LEAP trial were still protected at age 6, even after avoiding peanuts for a year.
The LEAP-Trio study included 508 teens who were in the original LEAP study. When tested for peanut allergy, only 4.4% of teens who ate peanuts in the original LEAP study had a peanut allergy, compared to 15.4% of children who avoided them. Eating peanuts early and regularly reduced the risk of peanut allergy by 71% compared to avoiding peanuts. This reduction in risk happened even if the children did not eat a lot of peanuts in later childhood.
The results of this study show feeding peanut to babies early gives lasting protection against peanut allergy, even if children did not keep eating peanuts regularly.
This reinforces current guidelines for parents and caregivers to introduce peanut early to infants. If used widely, this may prevent thousands of cases of peanut allergy. This strategy of early introducing other common food allergens to infants can also prevent food allergy compared to avoidance, but long-term studies need to be done to see if this protection persists later in childhood, like what this study showed for peanut.
Medical Review: June 2024 by Jerry Shier, MD
Stay in the loop - get news and research updates straight to your inbox with our e-newsletters.
Comments (0)